LivaNova (NASDAQ:LIVN) Rating Lowered to Hold at StockNews.com

LivaNova (NASDAQ:LIVN) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

LIVN has been the topic of several other research reports. Needham & Company LLC reissued a “buy” rating and set a $72.00 price objective on shares of LivaNova in a research note on Wednesday, March 20th. Robert W. Baird lifted their price objective on shares of LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research note on Thursday, February 22nd. Mizuho reissued a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research note on Wednesday, March 27th. Finally, Barclays raised their target price on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $64.40.

LivaNova Stock Performance

Shares of LIVN stock opened at $52.76 on Wednesday. The stock has a 50-day moving average of $53.55 and a 200-day moving average of $50.54. LivaNova has a one year low of $42.75 and a one year high of $59.86. The stock has a market cap of $2.85 billion, a PE ratio of 164.88 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. During the same quarter last year, the firm earned $0.81 EPS. LivaNova’s quarterly revenue was up 12.8% compared to the same quarter last year. As a group, sell-side analysts expect that LivaNova will post 3.01 earnings per share for the current year.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. acquired a new stake in shares of LivaNova in the third quarter valued at approximately $7,932,000. Kingdon Capital Management L.L.C. acquired a new stake in shares of LivaNova in the third quarter valued at approximately $7,123,000. Vanguard Group Inc. raised its holdings in shares of LivaNova by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after purchasing an additional 100,133 shares during the last quarter. Barclays PLC raised its holdings in shares of LivaNova by 15.9% in the third quarter. Barclays PLC now owns 851,870 shares of the company’s stock valued at $45,047,000 after purchasing an additional 116,842 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of LivaNova in the third quarter valued at approximately $1,672,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.